VAL-083 updated results, page-6

Disappointing OS results in recurrent...... (means VAL starts to be administered (a few months??) ...after initial treatment)

Does not provide OS for newly-diagnosed patients Why ? - but good initial PFS.

Lots of questions, at least on that report. Need to have a closer look at abstract.

QUOTE "Cancer cells utilize the PI3K pathway for the development of resistance to a broad range of anticancer treatments

Kintara looking for assistance with another drug in combo - and that drug starts with P, maybe.


_________________________________________________
For patients in the recurrent group receiving second-line therapy with VAL-083 following first-line TMZ failure, 84 patients have been enrolled as of the data cut-off of October 23, 2020 with 35 patients (34 efficacy evaluable) having received an initial dose of 40 mg/m²/day and 49 (43 efficacy evaluable) having received the planned Phase 3 initial dose of 30 mg/m²/day (on days 1, 2 and 3 of a 21-day cycle). Median overall survival (mOS) for the 77 efficacy evaluable patients who have completed at least once cycle of treatment was 7.6 months (CI 6.4-10.6 months). Additionally, for the 43 efficacy evaluable patients initially receiving the planned Phase 3 initial dose of 30 mg/m²/day, mOS is currently 8.5 months (CI 6.8-13.7 months). While this is not a head-to-head trial, historically, lomustine, which is the most commonly used chemotherapy for these patients, has demonstrated mOS of 7.2 months**

The overall survival achieved perfectly highlights what we have in Paxalisib.

QUOTE "Cancer cells utilize the PI3K pathway for the development of resistance to a broad range of anticancer treatments"......